WIRB-Copernicus Group acquires eConsent tech

By Melissa Fassbender

- Last updated on GMT

(Image: iStock/Ivanko_Brnjakovic)
(Image: iStock/Ivanko_Brnjakovic)
WIRB-Copernicus Group (WCG) has acquired eConsent technology to help clinical trial volunteers – and their families – make more informed decisions, says CEO.

Patient Genesis' ConsentNow electronic consent (eConsent) technology​ joins WCG’s platform of technology-enabled services.

WCG’s family of companies provide regulatory and ethical review services for human research.

We are convinced that by offering trial volunteers a more responsive and digitally-assisted way to learn about the trial of interest, they and their families will make a more informed and sustaining decision to participate​,” WCG Chairman and CEO Donald A. Deieso, Ph.D., told Outsourcing-Pharma.com.

Jeffrey Litwin, MD, CEO, MedAvante-ProPhase, a WCG company, told us that with ConsentNow, clients can “consistently deliver a concise message to potential subjects, clearly communicating the risks and benefits of participating in a clinical trial, with a proven process that can be tracked and measured​.”

The platform features step-by-step setup screens that document subject comprehension to ensure compliance. “Built-in subject retention tools, with real-time site and sponsor metrics, allow for comprehensive adjustments to the consent form if the desired learning level is not achieved​,” added Litwin.

Financial details of the transaction were not disclosed.

A suite of applications – and acquisitions

The clinical services organization has made several acquisitions in the past year, including​ that of the global patient recruitment, enrollment, and retention firm ThreeWire in May. In the same month, the company also announced​ its acquisition of MedAvante and ProPhase, a move that bolstered its presence in the central nervous system (CNS) and behavior health assessment markets.

Western IRB, a WIRB-Copernicus Group company, also aligned​ with the global professional services firm, Huron, in order to support research programs in the face of heightened expectations from industry sponsors. 

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars